Skip to content

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Gaucher Disease | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency...

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.

The objectives of the Registry are:

* To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Gaucher disease population.
* To evaluate the long-term effectiveness of imiglucerase and of eliglustat.

Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    0 and up

Critères de participation

Inclusion Criteria:

ICGG Gaucher Registry

* All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented β-glucocerebrosidase deficiency and/or mutation in the β-glucocerebrosidase gene.
* For all patients, appropriate patient authorization will be obtained.

Gaucher Pregnancy Sub-registry:

* be enrolled in the ICGG Gaucher Registry.
* be pregnant, or have been pregnant with appropriate medical documentation available.
* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.

Exclusion Criteria:

- No exclusion criteria for participation in the ICGG Gaucher Registry and Sub-registry.

Lieu de l'étude

Investigational Site Number : 124011
Investigational Site Number : 124011
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124005
Investigational Site Number : 124005
Kingston, Ontario
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124001
Investigational Site Number : 124001
Sherbrooke, Quebec
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124010
Investigational Site Number : 124010
Vancouver, British Columbia
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124024
Investigational Site Number : 124024
Kingston, Ontario
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124013
Investigational Site Number : 124013
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124014
Investigational Site Number : 124014
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124019
Investigational Site Number : 124019
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124021
Investigational Site Number : 124021
London, Ontario
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124002
Investigational Site Number : 124002
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124022
Investigational Site Number : 124022
Moncton, New Brunswick
Canada

Contactez l'équipe d'étude

Investigational Site Number : 124006
Investigational Site Number : 124006
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Étude parrainée par
Sanofi
Participants recherchés
Plus d'informations
ID de l'étude: NCT00358943